GDTC

CytoMed Therapeutics Ltd. (GDTC) | Rumor.io

CytoMed Therapeutics

GDTC

Attention (50-day avg)0%

Attention rank (50-day avg)#4,040

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization10.9M

Earnings per share-0.27

Dividend yield (TTM)—

Revenue (annual)324.4K

Net income (annual)-4M

Social

What share of all stock conversation is about GDTC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jul 24

The chairman of CytoMed Therapeutics Limited, Choo Chee Kong, has increased his stake in the company to 24.3% after purchasing 200,000 shares at $1.50.
CytoMed's stock price is up +53% after-hours, priced at $1.52, with key levels to watch at $1.88, $2.12, and $2.35.
The chairman's insider buy has been seen as a positive sign, with some investors taking a bullish stance on the stock, while others have warned of a potential short squeeze.

Generated by AI

Sentiment

Of the messages about GDTC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.32% +6.97
Bearish	—	—	—	5.68% -6.97

Bullish· Feb 5

$GDTC is a Singapore-based clinical-stage biotech developing allogeneic γδ T-cell immunotherapies, with a strong focus on cancer treatment.
The company has refuted "misleading claims" and reaffirmed clinical progress, sparking investor optimism and speculative buying.
With a low float and high trading volumes, $GDTC is experiencing a strong squeeze, with prices trending higher and potentially reaching $1.50 or more.

Bearish· Feb 5

$GDTC is experiencing a dominant downtrend that began in late January, despite a 19.4% price increase to $1.01.
The stock has erased all of its aftermarket gains in less than 3 hours, indicating a lack of sustained momentum.
$GDTC has a history of selling off after price increases, with some traders even shorting the stock due to its perceived value as a "junk" or "trash" investment.

Generated by AI

Topics

Of the messages about GDTC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	66.38%
Analysts	—	—	—	0%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	33.62%

Jan 6

CytoMed Therapeutics Limited (GDTC) has entered into a Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to advance the use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India.
The collaboration aims to assess the safety, tolerability, and efficacy of CytoMed's allogeneic gamma delta T cells in cancer treatment through a clinical research program, including a Phase 2 trial in India.
The agreement marks a significant step in CytoMed's efforts to develop and commercialize its allogeneic off-the-shelf Gamma Delta T Cells for the treatment of solid cancers, with potential for a major breakthrough in cancer treatment.

Generated by AI

Community

Of the messages about GDTC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	17.83%
Newcomers	—	100%	100%	82.17%

Feb 5

Newcomers are focusing on the potential for $GDTC to break through the $1.30 resistance level, with some setting targets as high as $1.80.
There is a mix of opinions on the asset's potential, with some expecting it to continue its upward trend and reach $1.40, while others are more cautious and suggest setting a stop-loss at $1.
The current price of $GDTC is around $1.19, and some users are looking for a move above $1.90 to confirm a new trend.

Generated by AI

Also Discussed

Investors talking about GDTC also mention

#	Name	Attention
1	Millennium Group International Holdings LimitedMGIH	0%0
2	Vsee Health Inc.VSEE	0%0
3	Fidelity Disruptive Medicine ETFFMED	0%0
4	Eaton Vance Short Duration Income ETFEVSD	0%0
5	Tradr 2X Long SPY Quarterly ETFSPYQ	0%new
6	WEBs Financial XLF Defined Volatility ETFDVXF	0%0
7	Granite YieldBoost QQQ FundTQQY	0%-0.02
8	Franklin Wireless Corp.FKWL	0%0
9	Wheeler Real Estate Investment Trust, Inc. 8.75% Preferred StockWHLRD	0%0
10	JBDI Holdings LimitedJBDI	0%0

CytoMed Therapeutics Ltd.

Healthcare
Biotechnology

CytoMed Therapeutics Ltd. is a Singapore-based biopharmaceutical company focused on developing cell-based immunotherapies for cancer and other serious diseases. Its current pipeline centers on innate immune cell and stem cell-based technologies, including gamma delta T-cell, natural killer T-cell, and pluripotent stem cell platforms designed to support novel therapeutic candidates. The company’s work includes research, development, processing, and banking of cells, with an emphasis on allogeneic approaches that use donor-derived materials. CytoMed Therapeutics Ltd. operates primarily in Singapore and Malaysia, serving the growing biotechnology and advanced therapy markets in Asia. Its role in the financial market is tied to the high-potential but research-intensive biopharmaceutical sector, where progress depends on clinical development, regulatory milestones, and platform innovation.

Website

Location

1 Commonwealth Lane

Singapore, 149544

Singapore

Social

What share of all stock conversation is about GDTC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jul 24

The chairman of CytoMed Therapeutics Limited, Choo Chee Kong, has increased his stake in the company to 24.3% after purchasing 200,000 shares at $1.50.
CytoMed's stock price is up +53% after-hours, priced at $1.52, with key levels to watch at $1.88, $2.12, and $2.35.
The chairman's insider buy has been seen as a positive sign, with some investors taking a bullish stance on the stock, while others have warned of a potential short squeeze.

Generated by AI

Sentiment

Of the messages about GDTC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.32% +6.97
Bearish	—	—	—	5.68% -6.97

Bullish· Feb 5

$GDTC is a Singapore-based clinical-stage biotech developing allogeneic γδ T-cell immunotherapies, with a strong focus on cancer treatment.
The company has refuted "misleading claims" and reaffirmed clinical progress, sparking investor optimism and speculative buying.
With a low float and high trading volumes, $GDTC is experiencing a strong squeeze, with prices trending higher and potentially reaching $1.50 or more.

Bearish· Feb 5

$GDTC is experiencing a dominant downtrend that began in late January, despite a 19.4% price increase to $1.01.
The stock has erased all of its aftermarket gains in less than 3 hours, indicating a lack of sustained momentum.
$GDTC has a history of selling off after price increases, with some traders even shorting the stock due to its perceived value as a "junk" or "trash" investment.

Generated by AI

Topics

Of the messages about GDTC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	66.38%
Analysts	—	—	—	0%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	33.62%

Jan 6

CytoMed Therapeutics Limited (GDTC) has entered into a Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to advance the use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India.
The collaboration aims to assess the safety, tolerability, and efficacy of CytoMed's allogeneic gamma delta T cells in cancer treatment through a clinical research program, including a Phase 2 trial in India.
The agreement marks a significant step in CytoMed's efforts to develop and commercialize its allogeneic off-the-shelf Gamma Delta T Cells for the treatment of solid cancers, with potential for a major breakthrough in cancer treatment.

Generated by AI

Community

Of the messages about GDTC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	17.83%
Newcomers	—	100%	100%	82.17%

Feb 5

Newcomers are focusing on the potential for $GDTC to break through the $1.30 resistance level, with some setting targets as high as $1.80.
There is a mix of opinions on the asset's potential, with some expecting it to continue its upward trend and reach $1.40, while others are more cautious and suggest setting a stop-loss at $1.
The current price of $GDTC is around $1.19, and some users are looking for a move above $1.90 to confirm a new trend.

Generated by AI

CytoMed Therapeutics

Social

Jul 24

Sentiment

Bullish· Feb 5

Bearish· Feb 5

Topics

Jan 6

Community

Feb 5

Also Discussed

CytoMed Therapeutics Ltd.

Company Information

Location

Also Discussed

Social

Jul 24

Sentiment

Bullish· Feb 5

Bearish· Feb 5

Topics

Jan 6

Community

Feb 5